title: Akebia saponin D attenuates ibotenic acid-induced cognitive deficits and pro-apoptotic response in rats: involvement of MAPK signal pathway.
abstract: Cholinergic deficit is one of the most remarkable symptoms and plays an important role in Alzheimer's disease. In the present study, the protective effects of Akebia saponin D (ASD) on learning and memory impairments induced by excitatory neurotoxin ibotenic acid injection were examined in vivo. Our findings suggest that ASD (90 mg/kg, p.o.) would exert a rescue effect on rats both in behavioral performances in Morris water maze and Y maze and cholinergic functions detected by chemical methods. We further investigated in the hippocampus and found ASD could regulate apoptosis-related proteins expression following ibotenic acid injection. Additionally, mitogen-activated protein kinase (MAPK) family phosphorylations were inhibited after ASD treatment, implicating that the MAPK signaling pathway could be involved in the mechanism underlying neuroprotection of ASD against ibotenic acid-induced excitotoxicity.
authors.affiliation: State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, 210009, Nanjing, PR China.
authors.forename: Xing
authors.initials: X
authors.lastname: Yu
authors.forename: Lin-na
authors.initials: LN
authors.lastname: Wang
authors.forename: Lin
authors.initials: L
authors.lastname: Ma
authors.forename: Ran
authors.initials: R
authors.lastname: You
authors.forename: Ran
authors.initials: R
authors.lastname: Cui
authors.forename: De
authors.initials: D
authors.lastname: Ji
authors.forename: Yue
authors.initials: Y
authors.lastname: Wu
authors.forename: Chun-feng
authors.initials: CF
authors.lastname: Zhang
authors.forename: Zhong-lin
authors.initials: ZL
authors.lastname: Yang
authors.forename: Hui
authors.initials: H
authors.lastname: Ji
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D003072:Cognition Disorders / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control* / Q000523:psychology; D004195:Disease Models, Animal; D006624:Hippocampus / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007051:Ibotenic Acid / Q000037:antagonists & inhibitors / Q000633:toxicity*; D020935:MAP Kinase Signaling System / Q000187:drug effects* / Q000502:physiology; D008297:Male; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology; D008568:Memory / Q000187:drug effects / Q000502:physiology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012503:Saponins / Q000494:pharmacology*
chemical_list: D018696:Neuroprotective Agents; D012503:Saponins; C534004:akebia saponin D; D007051:Ibotenic Acid; D002795:Choline O-Acetyltransferase; D000110:Acetylcholinesterase; D000109:Acetylcholine